Cargando…
Baicalin regulates the dopamine system to control the core symptoms of ADHD
We aimed to test the therapeutic effects of baicalin on attention deficit hyperactivity disorder (ADHD) in an animal model and to explain the potential mechanism. We investigated the therapeutic effects and mechanisms of baicalin in a spontaneously hypertensive rat (SHR) model of ADHD depending on t...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368814/ https://www.ncbi.nlm.nih.gov/pubmed/30736828 http://dx.doi.org/10.1186/s13041-019-0428-5 |
_version_ | 1783394070722248704 |
---|---|
author | Zhou, Rongyi Wang, Jiaojiao Han, Xinmin Ma, Bingxiang Yuan, Haixia Song, Yuchen |
author_facet | Zhou, Rongyi Wang, Jiaojiao Han, Xinmin Ma, Bingxiang Yuan, Haixia Song, Yuchen |
author_sort | Zhou, Rongyi |
collection | PubMed |
description | We aimed to test the therapeutic effects of baicalin on attention deficit hyperactivity disorder (ADHD) in an animal model and to explain the potential mechanism. We investigated the therapeutic effects and mechanisms of baicalin in a spontaneously hypertensive rat (SHR) model of ADHD depending on the dopamine (DA) deficit theory. In this study, fifty SHRs were randomly divided into five groups: methylphenidate (MPH), baicalin (50 mg/kg, 100 mg/kg, or 150 mg/kg), and saline-treated. Ten Wistar Kyoto (WKY) rats were used as controls. All rats were orally administered the treatment for four weeks. Motor activity, spatial learning and memory ability were assessed with the open-field and Morris water-maze tests. The mRNA and protein levels of tyrosine hydroxylase (TH), vesicular monoamine transporter 2 (VMAT2), synaptosomal-associated protein of molecular mass 25kD (SNAP25) and synataxin 1a in synaptosomes were detected with real-time polymerase chain reaction (PCR) and Western blot. In addition, DA levels were measured in the prefrontal cortex and striatum. The results indicated that both MPH and baicalin at doses of 150 mg/kg and 100 mg/kg significantly decreased the hyperactivity and improved the spatial learning memory deficit in the SHRs and increased the synaptosomal mRNA and protein levels of TH, SNAP25, VMAT2 and synataxin 1a compared with saline treatment. MPH significantly increased DA levels in both the prefrontal cortex (PFC) and striatum, while baicalin significantly increased DA levels only in the striatum. The results of the present study showed that baicalin treatment was effective for controlling the core symptoms of ADHD. Baicalin increased DA levels only in the striatum, which suggested that baicalin may target the striatum. The increased DA levels may partially be attributed to the increased mRNA and protein expression of TH, SNAP25, VMAT2, and syntaxin 1a. Therefore, these results suggested that the pharmacological effects of baicalin were associated with the synthesis, vesicular localization, and release of DA and might be effective in treating ADHD. However, further studies are required to better understand the molecular mechanisms underlying these findings. |
format | Online Article Text |
id | pubmed-6368814 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-63688142019-02-15 Baicalin regulates the dopamine system to control the core symptoms of ADHD Zhou, Rongyi Wang, Jiaojiao Han, Xinmin Ma, Bingxiang Yuan, Haixia Song, Yuchen Mol Brain Research We aimed to test the therapeutic effects of baicalin on attention deficit hyperactivity disorder (ADHD) in an animal model and to explain the potential mechanism. We investigated the therapeutic effects and mechanisms of baicalin in a spontaneously hypertensive rat (SHR) model of ADHD depending on the dopamine (DA) deficit theory. In this study, fifty SHRs were randomly divided into five groups: methylphenidate (MPH), baicalin (50 mg/kg, 100 mg/kg, or 150 mg/kg), and saline-treated. Ten Wistar Kyoto (WKY) rats were used as controls. All rats were orally administered the treatment for four weeks. Motor activity, spatial learning and memory ability were assessed with the open-field and Morris water-maze tests. The mRNA and protein levels of tyrosine hydroxylase (TH), vesicular monoamine transporter 2 (VMAT2), synaptosomal-associated protein of molecular mass 25kD (SNAP25) and synataxin 1a in synaptosomes were detected with real-time polymerase chain reaction (PCR) and Western blot. In addition, DA levels were measured in the prefrontal cortex and striatum. The results indicated that both MPH and baicalin at doses of 150 mg/kg and 100 mg/kg significantly decreased the hyperactivity and improved the spatial learning memory deficit in the SHRs and increased the synaptosomal mRNA and protein levels of TH, SNAP25, VMAT2 and synataxin 1a compared with saline treatment. MPH significantly increased DA levels in both the prefrontal cortex (PFC) and striatum, while baicalin significantly increased DA levels only in the striatum. The results of the present study showed that baicalin treatment was effective for controlling the core symptoms of ADHD. Baicalin increased DA levels only in the striatum, which suggested that baicalin may target the striatum. The increased DA levels may partially be attributed to the increased mRNA and protein expression of TH, SNAP25, VMAT2, and syntaxin 1a. Therefore, these results suggested that the pharmacological effects of baicalin were associated with the synthesis, vesicular localization, and release of DA and might be effective in treating ADHD. However, further studies are required to better understand the molecular mechanisms underlying these findings. BioMed Central 2019-02-08 /pmc/articles/PMC6368814/ /pubmed/30736828 http://dx.doi.org/10.1186/s13041-019-0428-5 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Zhou, Rongyi Wang, Jiaojiao Han, Xinmin Ma, Bingxiang Yuan, Haixia Song, Yuchen Baicalin regulates the dopamine system to control the core symptoms of ADHD |
title | Baicalin regulates the dopamine system to control the core symptoms of ADHD |
title_full | Baicalin regulates the dopamine system to control the core symptoms of ADHD |
title_fullStr | Baicalin regulates the dopamine system to control the core symptoms of ADHD |
title_full_unstemmed | Baicalin regulates the dopamine system to control the core symptoms of ADHD |
title_short | Baicalin regulates the dopamine system to control the core symptoms of ADHD |
title_sort | baicalin regulates the dopamine system to control the core symptoms of adhd |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368814/ https://www.ncbi.nlm.nih.gov/pubmed/30736828 http://dx.doi.org/10.1186/s13041-019-0428-5 |
work_keys_str_mv | AT zhourongyi baicalinregulatesthedopaminesystemtocontrolthecoresymptomsofadhd AT wangjiaojiao baicalinregulatesthedopaminesystemtocontrolthecoresymptomsofadhd AT hanxinmin baicalinregulatesthedopaminesystemtocontrolthecoresymptomsofadhd AT mabingxiang baicalinregulatesthedopaminesystemtocontrolthecoresymptomsofadhd AT yuanhaixia baicalinregulatesthedopaminesystemtocontrolthecoresymptomsofadhd AT songyuchen baicalinregulatesthedopaminesystemtocontrolthecoresymptomsofadhd |